Novartis Sees Differentiated Process for Biogenerics
Swiss pharmaceutical company Novartis expects regulators to develop diffentiated rules for approving generic biotechnology drugs, depending on their complexity, the company's chief executive told Reuters on Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article